Jenscare Scientific Co., Ltd (HKG: 9877), a leading device maker specializing in structural heart disease solutions, has announced the successful completion of a series of paid compassionate use cases for its innovative transjugular tricuspid valve replacement product, LuX-Valve Plus, across multiple hospitals in the Asia-Pacific region.
Clinical Success and Industry Recognition
The LuX-Valve Plus has garnered significant recognition within the medical community for its role in these cases, which included several rare instances of complex anatomical structures. Postoperative patients have shown marked improvements in clinical manifestations, cardiac function, and overall quality of life. These outcomes underscore the product’s broad applicability, high reliability, and user-friendly operation.
Global Expansion and Ongoing Trials
Jenscare is actively expanding the paid compassionate use of LuX-Valve Plus throughout the Asia-Pacific region. Concurrently, regulatory clinical trials for the product are underway in Europe and the United States, signaling the company’s commitment to global standards and the pursuit of broader market approval.-Fineline Info & Tech
